Tin tức & Cập nhật

The addition of relacorilant to nab-paclitaxel provides survival benefits in patients with platinum-resistant ovarian cancer (PROC) compared with weekly taxane, according to the results of the phase III ROSELLA study, presented at ESMO Gyn 2025.

In a systematic review and meta-analysis evaluating surgical outcomes in low rectal cancer patients who underwent early vs late ileostomy reversal, the former appears to be less beneficial than the latter in terms of surgical complications.

The addition of atezolizumab to first-line chemotherapy plus bevacizumab delivers significant improvements in survival among patients with PD-L1+ or PD-L1‒ persistent, recurrent, or metastatic (R/M) cervical cancer, results of a post hoc analysis of the BEATcc study have shown.

For patients who have undergone curative resection for nonmetastatic colorectal cancer (CRC), performing circulating tumour DNA (ctDNA) methylation analysis during surveillance facilitates earlier detection of recurrences suitable for curative therapy, according to interim data from the phase III FIND trial.